- ### Definition
  - AI-assisted drug discovery is the application of machine learning, deep learning, and generative modelling to accelerate and improve the identification, screening, and optimisation of candidate therapeutic compounds. Machine learning models predict molecular properties such as binding affinity, ADMET profiles (absorption, distribution, metabolism, excretion, toxicity), and off-target interactions from molecular structure representations. Generative models and graph neural networks are used to propose novel molecular scaffolds with desired properties. The field intersects cheminformatics, structural biology, and clinical informatics, and has seen significant acceleration from protein structure prediction tools such as AlphaFold.

- ### Semantic Classification
  - owl-class:: drug-discovery:Drug Discovery
  - owl-role:: Concept

- ### Relationships
  - uses [[Graph Neural Network]]
  - uses [[Generative Model]]
  - relatedTo [[Simulation]]
  - relatedTo [[Active Learning]]
  - relatedTo [[Clinical Trials]]

- ### Content
  - AI-assisted drug discovery addresses the high cost, high failure rate, and long timelines of traditional pharmaceutical research by applying machine learning to accelerate key stages of the discovery and development pipeline. The traditional pipeline proceeds from target identification through hit discovery, lead optimisation, preclinical testing, and eventually Clinical Trials — a process that often spans 10-15 years and costs over a billion pounds per approved drug.
  - Machine learning methods are applied at multiple stages. At the earliest stage, target identification uses genomic, proteomic, and clinical data to identify disease-relevant biological targets. Virtual screening uses deep learning models to predict the binding affinity of large compound libraries against a target, replacing or augmenting computationally expensive molecular docking Simulation. Generative chemistry models — including variational autoencoders, graph neural networks, and transformer-based architectures trained on molecular SMILES or graph representations — propose novel candidate molecules with optimised predicted properties. Reinforcement Learning combined with property prediction models guides de novo molecule generation towards desired pharmaceutical profiles.
  - AlphaFold, DeepMind's protein structure prediction system, has transformed structural biology by providing accurate 3D structures for hundreds of millions of proteins, enabling structure-based drug design at previously impossible scale. Active Learning frameworks iteratively select compounds for synthesis and experimental assay, maximising information gain per experiment. Multimodal models integrating genomic, transcriptomic, imaging, and clinical data are used for patient stratification and biomarker discovery to support Clinical Trials design. Despite significant investment from pharmaceutical companies, regulatory agencies require extensive empirical evidence of safety and efficacy that AI models alone cannot substitute.

- ### Provenance
  - sources::
  - migration-date:: 2026-05-19T00:00:00Z